keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrine tumor

keyword
https://www.readbyqxmd.com/read/28903383/association-between-abo-blood-types-and-sporadic-pancreatic-neuroendocrine-tumors-in-the-chinese-han-population
#1
Qiwen Ben, Jun Liu, Weiyi Wang, Fang Guo, Weiyan Yao, Jie Zhong, Yaozong Yuan
BACKGROUND: Although the relationship between non-O blood types and the risk of exocrine pancreatic cancer has been demonstrated, the association between ABO blood types and sporadic pancreatic neuroendocrine tumor (PNET) has not been reported thus far. METHODS: This hospital-based, case-control study included 387 patients with PNET and 542 age- and sex-matched controls. Unconditional multivariable logistic regression analysis was performed to estimate the adjusted odds ratios (AORs) and 95% confidence intervals (CIs)...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902738/false-positive-pancreatic-uptake-detected-on-68ga-psma-pet-ct-a-priority-changing-incidental-finding-while-assessing-the-need-for-a-prostate-biopsy
#2
Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Alan Alper Sag, Yersu Kapran
A 72-year-old man underwent Ga-PSMA PET/CT because of an elevated prostate-specific antigen level despite prior prostatectomy. Besides low-intensity prostatic PSMA reactivities, a faintly PSMA-positive lesion in the pancreatic corpus drew attention, which seemed suggestive of a primary pancreatic cancer on the subsequent MRI and therefore had to be excised. The final diagnosis was pT3 low-grade neuroendocrine tumor. PSMA-positive incidentalomas, detected on Ga-PSMA PET/CT, can reveal more clinically significant extraprostatic disorders...
September 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28900990/-prognostic-value-of-carcinoembryonic-antigen-alpha-fetoprotein-carbohydrate-antigen-125-and-carbohydrate-antigen-19-9-in-gastroenteropancreatic-neuroendocrine-neoplasms
#3
Luohai Chen, Yu Zhang, Minhu Chen, Jie Chen
OBJECTIVE: To study the rate of elevated common biomarkers of digestive tumors, including carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), carbohydrate antigen 125 (CA125) and carbohydrate antigen 19-9 (CA19-9), in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) and their prognostic values in GEP-NEN. METHODS: Clinicopathological data of patients with GEP-NEN treated in The First Affiliated Hospital, Sun Yat-sen University from January 2011 to December 2016 were retrospectively studied...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900985/-interpretation-and-evaluation-of-the-american-joint-committee-on-cancer-ajcc-8th-edition-staging-system-for-patients-with-gastroenteropancreatic-neuroendocrine-tumors
#4
Luohai Chen, Zhiwei Zhou, Jie Chen
American Joint Committeeon Cancer (AJCC) released the eighth edition staging system manual in October 2016. Based on the shortcomings in the seventh edition of AJCC staging system, staging classifications for gastroenteropancreatic neuroendocrine tumor (GEP-NET) were updated. The changes are as follow: small intestinal NET was divided into two groups, duodenal and jejunoileal NET and lymphatic metastasis was redefined into N1 and N2 in jejunoileal NET; stages were condensed except colorectal NET; the staging classification for pancreatic NET proposed by European Neuroendocrine Tumor Society(ENETS) was adopted...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28893836/immunotherapy-against-endocrine-malignancies-immune-checkpoint-inhibitors-lead-the-way
#5
Lucas Leite Cunha, Marjory Alana Marcello, Vinicius Rocha-Santos, Laura Sterian Ward
Immune checkpoint inhibitors are agents that act by inhibiting the mechanisms of immune escape displayed by various cancers. The success of immune checkpoint inhibitors against several tumors has promoted a new treatment strategy in clinical oncology, and this has encouraged physicians to increase the number of patients who receive the immune checkpoint therapy. In the present article, we review the main concepts regarding immune checkpoint mechanisms and how cancer disrupts them to undergo immune escape. In addition, we describe the most essential concepts related to immune checkpoint inhibitors...
September 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28892425/laparoscopic-resection-of-a-pancreatic-%C3%AE-cell-tumor-in-a-dog
#6
Janet Kovak Mcclaran, Philippa Pavia, Anthony J Fischetti, Taryn A Donovan
Laparoscopic partial pancreatectomy has been performed in experimental canine studies and has been evaluated in human medicine but has not been reported in a clinical veterinary case. The authors present a 9 yr old field spaniel with weakness and hypoglycemia with insulin levels and Amended Insulin: Glucose Ratio results equivocal for a pancreatic insulinoma. Multiple abdominal ultrasounds did not detect the tumor, yet dual-phase computed tomographic angiography revealed the presence of a focal hypoattenuating nodule in the left lobe of the pancreas...
September 11, 2017: Journal of the American Animal Hospital Association
https://www.readbyqxmd.com/read/28887784/pancreatic-neuroendocrine-tumor-in-a-patient-with-a-tsc1-variant-case-report-and-review-of-the-literature
#7
REVIEW
Parisa Mortaji, Katherine T Morris, Von Samedi, Steven Eberhardt, Shawnia Ryan
The majority of pancreatic neuroendocrine tumors (PNETs) are sporadic while 10-15% are attributable to one of several familial cancer syndromes. Hereditary forms are more commonly associated with Multiple Endocrine Neoplasia Type I and von Hippel Lindau Syndrome. However, patients with Tuberous sclerosis complex also have an increased incidence of PNETs. More often this has been reported in patients with TSC2 variants. In this case report, we summarize the literature regarding PNETs associated with Tuberous sclerosis complex, as well as present a case of a patient with a TSC1 variant and a PNET...
September 8, 2017: Familial Cancer
https://www.readbyqxmd.com/read/28884280/clinical-outcomes-of-everolimus-in-patients-with-advanced-nonfunctioning-pancreatic-neuroendocrine-tumors-a-multicenter-study-in-korea
#8
Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee
PURPOSE: Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS: Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included...
September 7, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28877814/limited-resection-of-the-duodenum-for-nonampullary-duodenal-tumors-with-review-of-the-literature
#9
REVIEW
Daisuke Hashimoto, Kota Arima, Akira Chikamoto, Katsunobu Taki, Risa Inoue, Takayoshi Kaida, Takaaki Higashi, Katsunori Imai, Toru Beppu, Hideo Baba
The surgical management of duodenal pathology is challenging because of its retroperitoneal position and shared blood supply with the pancreas. We present three types of limited resection of the duodenum for the removal of superficial or small nonampullary duodenal (NADL) lesions, and also a review of the English literature regarding management, such as endoscopic resection and limited duodenal resection. Ten cases underwent limited resections of the duodenum for superficial or small NADL lesions from 2011 to 2015...
November 1, 2016: American Surgeon
https://www.readbyqxmd.com/read/28875972/-gastroenterological-manifestations-of-von-hippel-lindau-disease-a-case-report
#10
Joanna Koniusz, Krzysztof Dąbkowski, Katarzyna Buczek, Aleksandra Gomółka, Teresa Starzyńska
Gastrointestinal organs are involved in the course of von Hippel Lindau disease. Typically pancreas in von Hippel Lindau syndrome is a site of cystic and solid tumors. Differential diagnosis of pancreatic lesions includes benign lesions (cysts, serous cystic adenomas), potentially malignant (neuroendocrine) and malignant tumors(metastases).In this work we present a patient with VHL syndrome with pancreatic cysts and neuroendocrine tumor.
August 21, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28875969/-gastroenterological-manifestations-of-von-hippel-lindau-disease
#11
EDITORIAL
Joanna Koniusz, Krzysztof Dąbkowski, Katarzyna Buczek, Aleksandra Gomółka, Teresa Starzyńska
Von Hippel-Lindau disease is rare autosomal dominant disorder that results from mutation of VHL gene. Typical manifestations of this syndrome include haemangioblastomas of retina, cerebellum and spinal cord, endolymphatic sac tumors, clear cell cancer and kidney cysts, pheochromocytoma, pancreatic cysts and neuroendocrine tumors. The differential diagnosis of pancreatic lesions in patients with von Hippel Lindau syndrome plays an important role. The pancreas in VHL disease is not only site of benign lesions (cysts, serous systic adenomas) but also of potentially malignant (neuroendocrine) and malignant tumors(metastases)...
August 21, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28874893/systemic-therapy-in-incurable-gastroenteropancreatic-neuroendocrine-tumours-a-clinical-practice-guideline
#12
S Singh, D Sivajohanathan, T Asmis, C Cho, N Hammad, C Law, R Wong, K Zbuk
PURPOSE: The purpose of the present review was to determine which antineoplastic systemic therapy is most effective in improving clinical outcomes for patients with incurable gastroenteropancreatic neuroendocrine tumours (nets). METHODS: A systematic search (2008-2016) of the literature in the medline and embase databases and the Cochrane Database of Systematic Reviews was conducted; abstracts from the American Society of Clinical Oncology, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, the European Society for Medical Oncology, the European Cancer Congress, the European Neuroendocrine Tumor Society, and the North American Neuroendocrine Tumor Society were reviewed...
August 2017: Current Oncology
https://www.readbyqxmd.com/read/28870964/incidence-and-oncological-implications-of-previously-undetected-tumor-multicentricity-following-pancreaticoduodenectomy-for-pancreatic-adenocarcinoma-in-patients-undergoing-salvage-pancreatectomy
#13
Andreas Andreou, Fritz Klein, Rosa B Schmuck, Daniela Lee, Marianne Sinn, Timm Denecke, Johann Pratschke, Marcus Bahra
BACKGROUND: The risk for multicentricity of pancreatic adenocarcinoma remains unclear and the question whether pancreaticoduodenectomy represents sufficient oncological treatment for patients with ductal adenocarcinoma of the head of the pancreas needs further investigation. PATIENTS AND METHODS: Clinicopathological data of patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma between 2005 and 2015 were assessed and the incidence of tumor multicentricity among patients who required salvage pancreatectomy within 90 postoperative days was evaluated...
September 2017: Anticancer Research
https://www.readbyqxmd.com/read/28870048/-the-treatment-options-of-pancreatic-neuroendocrine-neoplasm-with-liver-metastasis
#14
C H Yuan, L Y Tao, D R Xiu
Liver metastasis is the one of the main prognostic factors of pancreatic neuroendocrine neoplasm (PNEN). With the development of multidisciplinary collaboration among surgical oncology, medical oncology, and intervention treatment, the treatment of PNEN with liver metastasis gradually tends to become diversification. Surgery is still the only way for curing the patients with pancreatic neuroendocrine tumor with liver metastasis when the histological types are G1 and G2. Medical oncology and intervention treatment could be selected for those having PNEN with diffuse liver metastasis or those cannot tolerate surgery...
September 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/28867112/pet-computed-tomography-and-precision-medicine-in-pancreatic-adenocarcinoma-and-pancreatic-neuroendocrine-tumors
#15
REVIEW
Daniella F Pinho, Rathan M Subramaniam
(18)F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, (68)Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. (18)F-FDG PET/CT has a role in patients with poorly differentiated tumors...
October 2017: PET Clinics
https://www.readbyqxmd.com/read/28864881/improving-quality-of-life-in-patients-with-pancreatic-neuroendocrine-tumor-following-peptide-receptor-radionuclide-therapy-assessed-by-eortc-qlq-c30
#16
Milka Marinova, Martin Mücke, Lukas Mahlberg, Markus Essler, Henning Cuhls, Lukas Radbruch, Rupert Conrad, Hojjat Ahmadzadehfar
INTRODUCTION: Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors. The aim of this study was to evaluate changes in quality of life (QoL) of patients with P-NET following PRRT. METHODS: Sixty-eight patients with P-NET (31 female, mean age 61.4 y) underwent PRRT: 12 with NET of grade 1, 40 of grade 2, 8 of grade 3 (grade non-available n = 8)...
September 1, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28864682/mtor-kinase-inhibition-effectively-decreases-progression-of-a-subset-of-neuroendocrine-tumors-that-progress-on-rapalog-therapy-and-delays-cardiac-impairment
#17
Melissa A Orr-Asman, Zhengtao Chu, Min Jiang, Mariah Worley, Kathleen LaSance, Sheryl E Koch, Vinicius S Carreira, Hanan M Dahche, David R Plas, Kakajan Komurov, Xiaoyang Qi, Carol A Mercer, Lowell B Anthony, Jack Rubinstein, Hala Elnakat Thomas
Inhibition of mTOR signaling using the rapalog everolimus is an FDA-approved targeted therapy for patients with lung and gastroenteropancreatic neuroendocrine tumors (NETs). However, patients eventually progress on treatment, highlighting the need for additional therapies. We focused on pancreatic NETs (pNETs) and reasoned that treatment of these tumors upon progression on rapalog therapy, with an mTOR kinase inhibitor (mTORKi) such as CC-223 could overcome a number of resistance mechanisms in tumors and delay cardiac carcinoid disease...
September 1, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28859856/gastrin-induces-nuclear-export-and-proteasome-degradation-of-menin-in-enteric-glial-cells
#18
Sinju Sundaresan, Cameron A Meininger, Anthony J Kang, Amanda L Photenhauer, Michael M Hayes, Nirakar Sahoo, Jolanta Grembecka, Tomasz Cierpicki, Lin Ding, Thomas J Giordano, Tobias Else, David J Madrigal, Malcolm J Low, Fiona Campbell, Ann-Marie Baker, Haoxing Xu, Nicholas A Wright, Juanita L Merchant
BACKGROUND & AIMS: The multiple endocrine neoplasia, type 1 (MEN1) locus encodes the nuclear protein and tumor suppressor menin. MEN1 mutations frequently cause neuroendocrine tumors (NETs) such as gastrinomas, characterized by their predominant duodenal location and local metastasis at time of diagnosis. Diffuse gastrin cell hyperplasia precedes the appearance of MEN1 gastrinomas, which develop within submucosal Brunner's glands. We investigated how menin regulates expression of the gastrin gene and induces generation of submucosal gastrin-expressing cell hyperplasia...
August 28, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28838996/the-selective-tie2-inhibitor-rebastinib-blocks-recruitment-and-function-of-tie2hi-macrophages-in-breast-cancer-and-pancreatic-neuroendocrine-tumors
#19
Allison S Harney, George S Karagiannis, Jeanine Pignatelli, Bryan D Smith, Ece Kadioglu, Scott C Wise, Molly M Hood, Michael D Kaufman, Cynthia B Leary, Wei-Ping Lu, Gada Al-Ani, Xiaoming Chen, David Entenberg, Maja H Oktay, Yarong Wang, Lawrence Chun, Michele De Palma, Joan G Jones, Daniel L Flynn, John S Condeelis
Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation and metastasis, which can offset the effects of chemotherapy, radiation, and anti-angiogenic therapy. Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and pro-tumoral Tie2-expressing macrophages in mouse models of metastatic cancer. Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through reduction of Tie2+ myeloid cell infiltration, anti-angiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM)...
August 24, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28835083/-ct-and-mri-findings-of-primary-hepatic-neuroendocrine-neoplasm
#20
J K Li, M Wang, J Yuan, Z G Song
Objective: To study imaging features of primary hepatic neuroendocrine neoplasm (PHNEN) with CT and MRI. Methods: CT/MRI findings of ten patients with pathologically confirmed PHNEN were retrospectively analyzed. The result was compared with pathologic features classified by the 2010 WHO classification of gastro-entero-pancreatic neuroendocrine tumor which was also compared with the conventional method. Results: Six cases of neuroendocrine tumor (NET), all of which were classified as grade 2 (G2), consisted of 5 cases of carcinoid and 1 case of atypical carcinoid...
August 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
keyword
keyword
7197
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"